Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer - Concepedia

Concepedia

Publication | Closed Access

Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

245

Citations

31

References

2009

Year

Giuseppe Giaccone, Petr Zatloukal, Jaromı́r Roubec, Karijn Floor, J Musil, M Kůta, Rob J. van Klaveren, Subhash Chaudhary, Adrie Gunther, Setareh Shamsili

Journal of Clinical Oncology

Abstract

YM155 exhibited modest single-agent activity in patients with refractory, advanced NSCLC. A favorable safety/tolerability profile was reported. Further evaluation of YM155 in combination with chemotherapy and other targeted agents may be warranted.

References

	Year	Citations

Page 1